This list is an analysis based on recent market events. It's not an investment recommendation.
Established in 1989 and headquartered in Vienne, France, Eurofins Cerep SA delivers a broad spectrum of drug discovery support to pharmaceutical and biotechnology enterprises across the globe. The company's specialized offerings include the management of chemical compounds, high-throughput screening capabilities, in vitro safety assessments, optimization of lead compounds (SAR profiling), in vitro ADME evaluations, and in vivo pharmacokinetic (PK) studies. Furthermore, it provides expert services in assay development and design. The organization, originally known as Cerep SA, officially adopted the name Eurofins Cerep SA in June 2014.
FAQs
What is Eurofins Cerep stock price today?▼
The current price of ZEP2.MU is €4,925.50 EUR — it has increased by +0% in the past 24 hours. Watch Eurofins Cerep stock price performance more closely on the chart.
What is Eurofins Cerep stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Eurofins Cerep stocks are traded under the ticker ZEP2.MU.
Is Eurofins Cerep stock price growing?▼
ZEP2.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Eurofins Cerep has showed a +0% increase.
What is Eurofins Cerep market cap?▼
Today Eurofins Cerep has the market capitalization of 24.63M
What is Eurofins Cerep revenue for the last year?▼
Eurofins Cerep revenue for the last year amounts to 40.98M EUR.
What is Eurofins Cerep net income for the last year?▼
ZEP2.MU net income for the last year is 4.78M EUR.
How many employees does Eurofins Cerep have?▼
As of November 2, 2026, the company has 209 employees.
In which sector is Eurofins Cerep located?▼
Eurofins Cerep operates in the Health & Wellness sector.
When did Eurofins Cerep complete a stock split?▼
Eurofins Cerep has not had any recent stock splits.
Where is Eurofins Cerep headquartered?▼
Eurofins Cerep is headquartered in Vienne, France.